Curated News
By: NewsRamp Editorial Staff
July 18, 2024
Annovis Bio (NYSE: ANVS) Makes Strides in Neurodegenerative Disease Research with New Patent Filing
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Annovis Bio's new patent filing gives them a competitive advantage in the fight against neurodegenerative diseases.
- The patent covers solid forms of buntanetap, inhibiting the production of neurotoxic proteins, and builds upon a provisional patent.
- Annovis Bio's research aims to make significant strides in the fight against neurodegenerative diseases, potentially improving the lives of patients.
- The company's latest patent filing represents groundbreaking milestones in the field of neurodegenerative diseases.
Impact - Why it Matters
This news matters as it signifies a major breakthrough in the research and development efforts to address the unmet medical needs related to Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions.
Summary
Annovis Bio (NYSE: ANVS) has filed a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, building upon the provisional patent filed in June 2023. The company’s research focuses on inhibiting the production of multiple neurotoxic proteins that contribute to the progression of neurodegenerative diseases. This signifies a significant advancement in the ongoing fight against neurodegenerative conditions.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Annovis Bio (NYSE: ANVS) Makes Strides in Neurodegenerative Disease Research with New Patent Filing
